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Introduction
Unilateral vocal fold paralysis (UVFP) occurs most commonly following iatrogenic injury of the recurrent laryngeal nerve (RLN). 1 Natural recovery from RLN injuries may take 6 to 12 months, and most otolaryngologists wait at least 6 months before performing any sort of permanent surgical correction such as medialization thyroplasty, arytenoid adduction, or reinnervation. 1, 2 Following this "wait-and-see" approach, approximately 50% of patients will recover adequate laryngeal function and require no further intervention, some with true RLN recovery, but many with continued paralysis but good compensation from the uninvolved side. 3 Electromyographic studies show that most patients with UVFP have some measurable innervation, but it is either inadequate to provide functional adduction, or there are many adductor axons inappropriately reinnervating the abductor muscle (posterior cricoarytenoid, PCA), antagonizing the action of the adductor muscle group. 4 This innervation pattern is referred to as laryngeal synkinesis. 5 PCA muscle with a drug that inhibits reinnervation, thereby preventing adductor-to-abductor synkinesis and allowing more effective spontaneous adductor recovery. Reduced PCA tension should, at minimum, allow a more medial position of the paralyzed vocal fold. Initially, experiments were conducted to identify an injectable agent that could effectively block reinnervation, ideally with a single intramuscular injection to the PCA muscle. Vincristine, a vinca alkaloid chemotherapy drug, was found to be effective for this purpose, first in a rat femoral nerve crush injury model 7 and then in a rabbit facial nerve transection model. 8 McRae et al 9 independently confirmed that vincristine effectively blocked reinnervation in a rat RLN injury model.
This approach was then tested in the canine larynx. 6 In an RLN transection and re-anastomosis model, stimulated laryngeal adduction pressure (LAP), which serves as a proxy measure for the strength of laryngeal adduction, was found to achieve 73.1% of normal for larynges in which the PCA was injected with vincristine, compared with 56.1% for non-injected controls. 6 This finding has generated interest in testing this approach in a clinical trial. However, in the canine experiment, the vincristine injection was performed synchronous with the nerve transection injury. In practice, it is rare that the otolaryngologist has the opportunity to intervene on the same day as the injury; patients with UVFP are typically referred weeks or months after its onset. The previous work also showed that a vincristine injection does not affect existing innervation. 7 Thus, there is likely a window of opportunity following nerve injury in which a vincristine blockade can be effective, before significant reinnervation occurs. The present study was performed to confirm this hypothesis and to determine the treatment window in the canine model.
Methods and Materials
Twenty-seven purpose-bred, conditioned, female mongrel dogs weighing 20 to 25 kg were used in 7 study groups. The animals were maintained in a facility approved by the American Association for Accreditation of Laboratory Animal Care (AAALAC), and National Institutes of Health guidelines for animal care were followed strictly. All experiments were performed according to a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the Washington University School of Medicine.
Initial Procedure
Under general anesthesia, the neck was prepped with betadine solution and explored. A tracheotomy was performed as previously described, 10 and the endotracheal tube repositioned into it. Each RLN was dissected and a bipolar Harvard electrode was placed around it, 4 to 6 cm inferior to the cricothyroid joint, and connected to a custom laryngeal nerve stimulator. A second endotracheal tube was inserted into the tracheotomy and directed superiorly; the pilot line from the cuff was connected to a pressure transducer. Laryngeal adductor pressure (LAP) was measured by passing the inflated cuff (10 cc) between the vocal folds while stimulating 1 RLN. A supramaximal stimulus level ensures that all RLN axons are depolarized; the LAP is the net squeeze on the cuff caused by the simultaneous co-contraction of all of the adductor/agonist muscles plus the abductor/antagonist PCA muscle. 11 The responses are frequency-dependent and reach a maximum adduction plateau at stimuli of 70 Hz and above. LAP measurements were made at 10 Hz intervals up to 100 Hz. A second set of measurements was made with the stimulator connected to the contralateral electrode. The 2 sides are independent, allowing 2 experiments to be performed on each subject.
RLN Injury Model
For 6 of the 7 study groups, a standard transection and repair model was performed. The RLN was transected 4 cm inferior to the cricothyroid joint and then immediately reanastomosed end-to-end using an operating microscope and 9-0 nylon sutures. The orientation of the stumps was random (in a previous study, the same result was obtained with a precise realignment as with an 180 o rotation of the stumps 12 ). The stoma was matured and the wounds were closed.
Experimental Groups
Animals were randomly assigned to interventions as shown in Table 1 . For animals receiving injections at time zero (groups B, F, and G), 0.4 mg vincristine was injected directly into each PCA muscle prior to initial wound closure. For those receiving injections at a later time (groups C, D, and E), the superior aspect of the wound was opened under general anesthesia and the same vincristine injection procedure was followed. In a pilot experiment in 3 terminal dogs from other studies, in which PCA injections were attempted transorally using methylene blue, the dye was found to be deposited within the target muscle in only 4 of 6 PCAs; so an open injection procedure was chosen for this study to be certain of accurate placement.
Terminal Procedure
Six months after the initial surgical procedure (12 months for group F), the animals underwent general anesthesia. The RLNs were identified and dissected near the sternum, several centimeters inferior to the site of previous nerve transection and repair, and electrodes applied. The LAP data were collected using the same endotracheal tube that was used at the initial procedure. The larynges were harvested for histochemical analysis (not included in this report).
Data Analysis
At each frequency, LAP measurements were made with 3 passes of the endotracheal tube; the highest recorded pressure was used. The 4 adductor plateau values (at 70, 80, 90, and 100 Hz) were averaged for each animal. The final mean LAP value was expressed as a fraction of the initial (pretreatment) value. Some of the animals had no measurable LAP at the end of the experiment; these were excluded from the averages. Comparisons between groups were made using a 2-tailed Student t test; differences were considered significant if P < .05.
Pharmacological Measures
In 2 additional animals, vincristine was given as described previously, and blood samples were drawn at various time intervals over the next 3 days. Maximum levels were determined on the day of sacrifice by delivering the same total vincristine dose intravenously and drawing a blood sample 30 minutes later. The plasma was separated by centrifuge, then frozen and sent to an analytic pharmacology lab for determination of vincristine levels.
Results
Four animals expired 1 to 3 months after their initial procedure: 1 from a mucus plug occluding the tracheastoma, 1 from a severe pulmonary infection, and 2 from unknown causes. There were no other complications. Twenty-three animals completed the 46 planned experiments as shown in Table 1 .
Results for all study groups are given in Table 2 . For group A (transection/repair control, no vincristine), the mean LAP for the 8 experiments in this study was 54.9% of pretreatment baseline, consistent with the result reported previously. 12 Group B (vincristine injection at time zero) LAP results were also similar to the previous study with a mean value of 70.9%. These previous results were added to the new data from the present study to create larger comparison groups and strengthen the statistics, as delineated in Table 2 . These pooled results were used for subsequent comparisons as well as for the plot in Figure 1 . Combined data from this study and prior study.
Group C (vincristine injection after a 3-month delay) showed the same improvement in adductor function as group B with no delay. It is reasonable to surmise that other delay times less than 3 months would give similar results. However, group E (5-month delay) did not show any vincristine benefit, and group D (4-month delay) had an intermediate result that was not statistically different from the no-vincristine control group (A). Thus, the data support vincristine blockade of the PCA as an early intervention that may improve ultimate adductor function after RLN injury if given within 3 months of injury.
Group F dogs received vincristine injections at time zero and then were allowed 12 months of healing prior to data collection in order to assess a longer-term result. This group exhibited remarkably complete recovery of adductor strength, with LAP measures that were even higher than pretreatment values. This degree of recovery cannot be accounted for by PCA blockade alone but instead suggests there must have been adductor reinnervation contributions from other nearby nerves (that are somehow activated when the RLN is stimulated). A suitable non-vincristine 12-month control group is needed to better explore this possibility.
Group G was studied to confirm the previous finding in the rat model that vincristine injection does not affect muscles that are already innervated. As seen in Figure 1 , the LAP in these 4 experiments was essentially unchanged from pretreatment baseline by the injection. It also confirms that the LAP methodology is repeatable and reliable.
Mean vincristine levels are shown in Figure 2 . It can be seen that the peak plasma level following intramuscular PCA injection is 19% of the maximum level determine by direct intravenous injection, suggesting that 81% of the vincristine remained within the muscle. The levels followed a typical logarithmic decay with an excellent fit (R 2 = 0.985), with the animal clearing 7% of the circulating vincristine per hour (the exponent in the line of best fit).
Discussion
This study demonstrates that an early (≤3 months postinjury) vincristine injection to the PCA muscle can effectively block synkinetic reinnervation of that antagonistic muscle, potentially leading to more complete or stronger adductor recovery. Current interventions for treating UVFP focus on moving the vocal fold to a more medial position; blocking reinnervation of the antagonist PCA muscle by vincristine injection is a simple approach that may achieve this without the need for more invasive procedures such as thyroplasty. This study did not formally assess vocal fold position, but laryngoscopy at the terminal procedure did suggest a more medial resting position, and many of the dogs could actively close the vocal folds completely despite the bilateral RLN transection injuries and generate a loud bark. The stimulated LAP was chosen as a proxy for adductor function because it can be repeated over time without regard to subtle changes in the healing milieu that might affect other measures. For example, it is observed during these experiments that sanguinous collections around the electrode can alter the stimulation threshold of the RLN. The use of supramaximal stimulation overcomes this potential problem; the stimulating current can simply be increased as needed to stay supramaximal. The stimulated laryngeal adduction is a non-physiologic construct; in nature, the adductor muscles and PCA muscle likely never simultaneously co-contract maximally. But this experimental design enables a reliable repeat measure of the function of interest. It is unknown how the measured changes in LAP will translate into clinical benefit, namely, whether a 10% to 20% increase in adductor pressure will provide meaningful benefit to patients. This can only be determined with a clinical trial.
The hypothesis that there is a therapeutic window of opportunity was confirmed by these data. The measured benefit of vincristine injection was the same if the drug was given at the time of nerve injury as it was if given 3 months later but not 4 or more months later. This window is likely a function of the site of injury. The lesion in this study was created 4 cm inferior to the cricothyroid joint; lesions that are more proximal, such as in the thoracic cavity, can be expected to require more time for the axons to grow over the longer distance to reach the laryngeal muscles, and the window of opportunity would be expected to stay open a little longer, perhaps to 4 months. The canine model is a good model for the expected time frame of recovery in human subjects with RLN injuries, and these findings are likely to translate well to human trials. It would be reasonable to use a 3-month window as the limit for the first human studies of this "new paradigm."
There are occasional situations when the otolaryngologist does have a chance to treat a patient on the same day as an RLN injury. Sometimes the RLN is sacrificed in thyroid cancer surgery; sometimes it is transected intentionally in order to perform an end-to-end anastomosis for a laryngeal reinnervation procedure. In these situations, a vincristine injection could be performed as a part of the surgical therapy, and the potential benefit demonstrated by the "time zero" injection groups in this study would apply.
A vincristine blockade of the PCA muscle would also prevent non-synkinetic reinnervation of the PCA (although the vincristine block is incomplete). If this approach is applied clinically, it must be used with the knowledge that some of the "normal" reinnervation of the PCA muscle that might have otherwise occurred will be relinquished. An incomplete block is likely preferable, as some PCA tone is desirable to stabilize the arytenoid on the cricoid. Anteroinferior displacement of the arytenoid was not seen in any of the animals in this study. Vincristine is associated with certain side effects when used for chemotherapy; however, the usual human adult systemic dose of 1.4 mg/m 2 (2.6 mg for a 70 kg patient) daily is substantially more than the single intramuscular dose of 0.4 mg used in this study (the recommended limit in dogs is 0.75 mg/m 2 or 0.6 mg for the dogs in this study). If patients undergo this treatment they will have to be monitored for toxicities, but the risk seems low. In order to evaluate this intervention in a clinical trial, some additional steps will be needed: (1) completion of histologic study of harvested PCA muscles and overlying mucosa, to demonstrate lack of local reaction to intramuscular injection (grossly, there appears to be no reaction); (2) approval from FDA to use intramuscular vincristine in a human trial (currently it is approved for intravenous use only); (3) appropriate IRB approval with safety monitoring committee. These steps have been initiated. It would be preferable to administer these injections to patients transorally via laryngoscopy, which may require general anesthesia for location certainty.
Conclusion
In the canine model, a single vincristine injection to the PCA muscle shortly after RLN transection and reanastomosis leads to improved adductor function at 6 months postinjury. The injection needs to be given within 3 months of the nerve trauma; vincristine injection into an innervated muscle has no significant effect. This approach may offer a simple means to prevent some synkinesis and to reduce the number of unilateral vocal fold paralysis patients that ultimately need more involved rehabilitation procedures such as thyroplasty.
